@FierceMedDev: ICYMI yesterday: AstraZeneca, NCI tap French company to develop companion mobile app for cancer drugs. Article | Follow @FierceMedDev
@EmilyWFierce: Google Life Sciences will now be known as "Verily." More | Follow @EmilyWFierce
> Upstart wins CE mark for first swallowable weight-loss gastric balloon. Article
> Minimally invasive cardiovascular company Spectranetics ($SPNC) has raised $110 million in a credit facility led by Midcap Financial and Silicon Valley Bank. It's intend to back the company through the U.S. launch of drug-coated balloon Stellarex, which it acquired from Covidien in January for an undisclosed sum. Spectranetics intends to submit a PMA to FDA for Stellarex. More
> Four new board members have been chosen for the National Medical Device Evaluation System Planning Board, which is slated to create a national system for medical device postmarket surveillance and evaluation. These are Mark Deem, a managing partner at The Foundry; Barbara Evans, George Butler Research Professor and Director of the Center for Biotechnology and Law at University of Houston Law Center; Bill Murray, President and CEO of the Medical Device Innovation Consortium; and Kenneth Reali, president and CEO of Clinical Innovations. More
> Aesthetics players Galderma and Zeltiq ($ZLTQ) have partnered to market each other's offerings for facial rejuvenation and non-invasive fat reduction, respectively. More
Biotech News
@FierceBiotech: Busy Roche inks another immuno-oncology discovery pact, this time with Pieris. News | Follow @FierceBiotech
@JohnCFierce: In the category of 'can't make this stuff up,' $NWBO issued a followup statement saying why Leary wouldn't work. More | Follow @JohnCFierce
> Pfizer bets up to $1B on BioAtla's approach to immuno-oncology. More
> Alexion grabs an FDA OK--the 41st of '15--for rare-disease drug Kanuma. News
> Sitting on $25B, Gilead goes shopping for high-dollar buyouts. Article
Pharma News
@FiercePharma: Japan's Kaketsuken at center of major vaccine, blood product records fraud. FiercePharmaAsia story | Follow @FiercePharma
@CarlyHFierce: J&J, AbbVie's Imbruvica builds on case for first-line CLL use at ASH. More | Follow @CarlyHFierce
> Beleaguered Daiichi Sankyo shuttering German antibody business. News
> Valeant weighs Paragon sale to get out of FTC spotlight. Story
Drug Delivery News
> 'Smart' hydrogel wound dressing delivers drugs from reservoirs. News
> FDA funds computer simulations in bid to speed up development of long-acting generics. Story
> Clearside closes $20M round for candidates that are injected into the eye's suprachoroidal space. More
> University of Warwick spinout develops first transdermal ibuprofen pain patch. Report
> Metal 'nano-terminator' liquefies on demand to bring cancer down. Article
Pharma Manufacturing News
> FDA gives Sun Pharma go-ahead to manufacture generic version of cancer drug Gleevec. Item
> Associated Press: Taxpayers' tally to entice Novo Nordisk to NC may top $130M. More
> South African health activists protest Sanofi over lack of BCG vaccine. Article
> Catalent production issues at French plant cause delay in GSK launch. Story
> AstraZeneca shuttering Bengaluru, India API plant, citing low demand. Report
Pharma Asia News
> China economy not the main culprit in pharma slowdown, FT says. Article
> Outlook for early 2016 in Asia sees headwinds for Japan, India and Thailand. Report
> Japan's Kaketsuken at center of major vaccine, blood product records fraud. More
> China superbug has already gone global, Danish researcher says. Story
> India a potential center for orphan drug development and demand. Article